FDA Has Three LDT Cards to Play. How Will It Play Them?

As a clinical lab insider told me Monday morning, before the first of the two-day public meeting even began, that whatever the FDA's final decision will be, the "vast majority" of its components have already been set in soft stone.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.